2018
A potent prolyl tRNA synthetase inhibitor antagonizes Chikungunya and Dengue viruses
Hwang J, Jiang A, Fikrig E. A potent prolyl tRNA synthetase inhibitor antagonizes Chikungunya and Dengue viruses. Antiviral Research 2018, 161: 163-168. PMID: 30521835, PMCID: PMC6345585, DOI: 10.1016/j.antiviral.2018.11.017.Peer-Reviewed Original ResearchConceptsDengue virusSignificant morbiditySafe vaccineSynthetase inhibitionEndemic areasSynthetase inhibitorFlavivirus genusMosquito-bornePotent antagonistHost factorsGroup of pathogensVirusMultiple virusesChikungunyaHematophagous arthropod vectorsAedes sppArthropod vectorsEpidemic pathogensAdditional approachesMorbidityPathogensVaccineAntagonistMortalityHuman population
1994
A Recombinant OspA and OspB Based Lyme Disease Vaccine
Fikrig E, Kantor F, Barthold S, Flavell R. A Recombinant OspA and OspB Based Lyme Disease Vaccine. NATO Science Series A: 1994, 25-31. DOI: 10.1007/978-1-4615-2415-1_5.Peer-Reviewed Original Research
1987
Epidemiology of American Cutaneous Leishmaniasis Due to Leishmania braziliensis brasiliensis
Jones T, Johnson W, Barretto A, Lago E, Badaro R, Cerf B, Reed S, Netto E, Tada M, Franca F, Wiese K, Golightly L, Fikrig E, Costa J, Cuba C, Marsden P. Epidemiology of American Cutaneous Leishmaniasis Due to Leishmania braziliensis brasiliensis. The Journal Of Infectious Diseases 1987, 156: 73-83. PMID: 3598227, DOI: 10.1093/infdis/156.1.73.Peer-Reviewed Original ResearchConceptsPrimary lesionMucosal diseaseCutaneous leishmaniasisFive-year prospective studyLeishmania braziliensis braziliensisYears of ageAmerican cutaneous leishmaniasisAntimony therapyAnnual incidenceSkin testingProspective studyRecent lesionsSkin testSkin lesionsEndemic areasPatientsLesionsDiseaseMost diseasesLeishmaniasisYearsTherapyEpidemiologyPrevalenceIncidence